Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Read more about Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Read more about Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Read more about Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Read more about Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Read more about Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Treatment of medulloblastoma with a modified measles virus. Read more about Treatment of medulloblastoma with a modified measles virus.
Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Read more about Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Read more about Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Read more about MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Read more about Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
